跳至主要内容
临床试验/NCT03074526
NCT03074526已完成不适用

Prospective, Double Blinded Randomized Multi-Center Controlled Trial Evaluating the 2 Different Doses of Lyophilized Amniotic Fluid Compared to a Saline Placebo Injection in the Treatment of Subjects With Osteoarthritic (OA) Knee Pain

MiMedx Group, Inc.8 个研究点 分布在 1 个国家目标入组 156 人开始时间: 2017年1月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
156
试验地点
8
主要终点
Reduction in Pain

研究概览

简要总结

To evaluate the efficacy of Lyophilized amniotic fluid as compared to the Saline Injection, placebo control in the treatment of moderate osteoarthritis of the knee.

详细描述

Approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, Saline Placebo and 4ml 2x). The estimated enrollment period is 6 months. Each subject will receive 1 injection and be evaluated for efficacy and safety during a 6 month observation period. The study is expected to be completed within 12 months, inclusive of enrollment and follow-up for all subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
30 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is 30 years or older.
  • Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren Lawrence grading scale.
  • Subject is willing and able provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study.
  • Subject must have a VAS pain scale greater than 30.

排除标准

  • Subject has active infection at the injection site.
  • Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain.
  • BMI greater than 45 kg/m2
  • Subject has received an intra-articular hyaluronic acid (HA) injection for the treatment of OA of the target knee within 12 weeks prior to screening.
  • Subject has received a steroid or platelet rich plasma (PRP) injection for the treatment of OA of the target knee within 12 weeks prior to screening.
  • Subject has had major surgery or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment.
  • Subject is pregnant or plans to become pregnant within 180 days of treatment.
  • Subject has used an investigational drug, device or biologic within 12 weeks prior to treatment.
  • Subject has any significant medical condition that, in the opinion of the Investigator, would interfere with protocol evaluation and participation.
  • Subject has a history of immunosuppressive or chemotherapy in the last 5 years
  • Subject has autoimmune disease or a known history of having Acquired Immunodeficiency Syndromes (AIDS) or HIV
  • Subject has had prior radiation at the site
  • Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin)
  • New diagnosis of gout in the past 6 month
  • Subject has a diagnosis of osteoarthritis (OA) defined as Grade 4 on the Kellgren Lawrence grading scale.
  • Subject has a diagnosis of Osteonecrosis of the knee.
  • Subject has had a total knee replacement.

结局指标

主要结局

Reduction in Pain

时间窗: 3 month

The proportion of subjects who experience at least 20% improvement over baseline in Visual Analog Scale for Pain at 3 months in the Lyophilized amniotic fluid Injectable versus placebo-treated group.

次要结局

  • Range of Motion(3 months)
  • Knee Injury and Osteoarthritis Outcome Score(4weeks, 6weeks, 3 months, 16 weeks, 6 months)
  • SF-12 Health Health Survey(4weeks, 6weeks, 3 months, 16 weeks, 6 months)
  • Activity of Daily Living Questionnaire(4weeks, 6weeks, 3 months, 16 weeks, 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验